Form D · Biotechnology
Invizyne Technologies Inc
Monrovia, CA · CIK 0002010788
Offering snapshot reported Nov 19, 2024 · SEC filing
- Reported sold
- $11.7K Offering amount: $11.7K
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $1K Reported outside-investor minimum
- First sale
- Nov 14, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 19, 2024 | Initial | $11,718 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-529770
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Public Ventures LLC d/b/a MDB Capital | 42677 |
Source: Form D, filed Nov 19, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Lon Bell | Director |
| James Bowie | Director |
| Anthony Di Giandomenico | Director |
| Mohammad Hayat | Director, Executive |
| Michael Heltzen | Executive |
| James Lalonde | Director |
| Christopher Marlett | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
750 Royal Oaks Dr
Monrovia, CA, 91016
Monrovia, CA, 91016